TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

Acta Biomedica Scientia

Volume 6, Issue 3, 2019
Mcmed International
Acta Biomedica Scientia
Issn
2348 - 215X (Print), 2348 - 2168 (Online)
Frequency
bi-annual
Email
editorabs@mcmed.us
Journal Home page
http://mcmed.us/journal/abs
Recommend to
Purchase
Abstract
Title
IN CLINICAL PRACTICE IGE LEVELS AS A BIOMARKER FOR THE MANAGEMENT OF BRONCHIAL ASTHMA PATIENTS IN INDIA
Author
SubramanyamC1*, Madine Subbaramu
Email
nithishent@gmail.com
keyword
Allergic asthma-; Serum IgE; Severity of obstruction; Spirometry-IgE therapy.
Abstract
Allergen-specifcIgE is the predominant biomarker for allergic asthma. IgE binds to Fc?RI, which is expressed by several cells including mast cells, basophils, eosinophils, and B lymphocytes. Te subsequent binding of allergens to allergenspecifcIgE activates the release of proinfammatory mediators. It was also determined that serum IgE levels were associated with airway hyper-responsiveness, even in patients without a history of asthma symptoms or atopy. Therefore, a study was undertaken to estimate the serum IgE level in bronchial asthma patients, and to correlate the severity of airway obstruction with serum IgE level in bronchial asthma patients. This cross-sectional study was carried out in Tertiary Care Hospitals of NRI Medical College and General Hospital Chinakakani and Sri Lakshmi Narayana Institute of Medical Sciences, Pondicherry. Our Results concludes that the serum IgE level in bronchial asthma patients is elevated and it increases with the increase in the severity of airway obstruction which paves the way for better understanding about the nature of disease and disease progression. Serum IgE level increases as the severity of airflow obstruction increases. It helps to classify the Bronchial asthma patients based on IgE and to guide anti IgE therapy for the patients with difficult to treat allergic asthma and to assess its response
Back to Top >>>>